The invention relates to a family of compounds derived from chromenopyrazole of formula (I), which have the capacity to modulate the receptor of the family of the GPR55 cannabinoids, the invention therefore also relating to the use of said compounds for producing a medicament for treating diseases in which the GPR55 receptor has a physiological role, such as diabetes, Parkinson's disease, multiple sclerosis, neuropathic pain, osteoporosis and cancers such as cholangiocarcinoma, breast cancer, ovarian cancer and prostate cancer, glioblastoma and cutaneous carcinoma.